Morningstar US Small Growth Rating $13.91 0.00 (0.00%) As of 08/22/2025 Add Compare Share Share Ratings Stock AnalysisChartRatingsBuy This Stock Morningstar US Small Growth Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.MSGR Aggregate RatingModerate Buy 2.62Holdings in MSGR have an aggregate rating of Moderate Buy based on 276 analyst ratings issued in the past year covering 21 companies (90.8% of the portfolio).MSGR Aggregate Price Target$13.91High Prediction$13.91Average Prediction$13.91Low Prediction$13.91Holdings in MSGR have an aggregate price target of $13.91 and a range of $13.91 to $13.91 covering 21 companies (90.8% of the portfolio).MSGR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy8 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Morningstar US Small Growth Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 MSGR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings8.06%VRTXVertex Pharmaceuticals$389.05-1.5%4.9571 of 5 stars2.56$497.10 27.8%27Positive NewsAnalyst Downgrade7.99%SCLXScilex$18.26-3.2%2.398 of 5 stars2.50$455.00 2,391.8%47.01%ARCTArcturus Therapeutics$17.76-4.0%2.6076 of 5 stars3.00$50.57 184.7%8Analyst Forecast6.62%ALNYAlnylam Pharmaceuticals$443.71-2.3%4.1411 of 5 stars2.85$405.33 -8.6%266.44%MRNAModerna$25.41-6.3%4.6394 of 5 stars2.04$42.88 68.8%24Analyst Forecast6.17%BNTXBioNTech$105.22-5.1%2.8403 of 5 stars2.76$135.80 29.1%175.97%SRPTSarepta Therapeutics$18.09-10.5%4.5596 of 5 stars2.07$43.50 140.5%29Trending NewsAnalyst Forecast5.78%PTCTPTC Therapeutics$49.27-2.6%4.3534 of 5 stars2.63$69.15 40.4%16Analyst Revision4.94%MRVIMaravai LifeSciences$2.41-1.8%4.0087 of 5 stars2.25$5.75 139.1%12Gap Up4.29%NTLAIntellia Therapeutics$11.39+8.3%4.6079 of 5 stars2.58$29.05 155.1%19Positive NewsInsider TradeGap Up4.24%IONSIonis Pharmaceuticals$41.85-2.0%4.5694 of 5 stars2.86$60.92 45.6%14Trending NewsAnalyst ForecastAnalyst Revision3.19%RNAAvidity Biosciences$45.28-2.3%3.1527 of 5 stars3.06$67.00 48.0%18Positive NewsInsider Trade3.19%CVACCureVac$5.42-0.4%4.6409 of 5 stars2.20$6.83 26.1%5Earnings Report3.18%ARWRArrowhead Pharmaceuticals$20.73-2.8%3.649 of 5 stars3.00$43.14 108.1%9Positive News2.95%ABUSArbutus Biopharma$3.50-2.6%2.6976 of 5 stars3.00$5.50 57.4%4News CoveragePositive News2.59%DYNDyne Therapeutics$13.04+3.6%3.7502 of 5 stars3.06$34.07 161.3%16Positive NewsAnalyst UpgradeGap Up2.10%SGMOSangamo Therapeutics$0.55-5.5%2.5757 of 5 stars2.67$4.50 712.3%61.84%STOKStoke Therapeutics$18.88-3.5%4.5588 of 5 stars3.22$25.57 35.4%91.53%HLVXHilleVax$2.13+3.2%1.1281 of 5 stars2.00$2.00 -5.9%21.52%PRQRProQR Therapeutics$2.26-0.2%2.8101 of 5 stars3.13$8.00 254.8%81.20%PEPGPepGen$1.32-0.4%3.2039 of 5 stars2.33$7.67 483.0%3 This page (NYSEARCA:MSGR) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morningstar US Small Growth Please log in to your account or sign up in order to add this asset to your watchlist. Share Morningstar US Small Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access